Skip to main content
Clinical Trials/CTRI/2022/02/040442
CTRI/2022/02/040442
Not yet recruiting
Phase 3

Comparative study between weekly dose of 50mg Mifepristone and daily dose of 25 mg Mifepristone in medical management of UTERINE FIBROID

Dr Subhasri S0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Subhasri S
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Subhasri S

Eligibility Criteria

Inclusion Criteria

  • Women of age group 30\-45
  • Women with symptomatic fibroid
  • Fibroid size 3\-5cm
  • Without endometrial hyperplasia

Exclusion Criteria

  • Uterine size more than 12weeks
  • Associated cervical or tubal lesions
  • Fibroid with severe anemia
  • Hepatic and renal dysfunction
  • Endometrial hyperplasia

Outcomes

Primary Outcomes

Not specified

Similar Trials